La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
40 hedge funds and large institutions have $184M invested in La Jolla Pharmaceutical Company in 2015 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
14% more funds holding
Funds holding: 35 → 40 (+5)
5% more capital invested
Capital invested by funds: $176M → $184M (+$8.19M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
66% less call options, than puts
Call options by funds: $150K | Put options by funds: $446K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.2M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$4.36M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.03M |
| 4 |
VAM
Visium Asset Management
New York
|
+$1.64M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$8.47M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$5.28M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.85M |
| 4 |
RA
Royce & Associates
New York
|
-$1.11M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.07M |
LJPC Hedge Fund Activity: Q1 2015 in Review
40 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q1 2015, worth a combined $184M — up 4.6% from $176M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LJPC positions and 5 closed out — a net gain of 5 holders — while 15 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $16.2M. The largest seller was Broadfin Capital, cutting an estimated $8.47M.
- 40 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q1 2015, up from 35 in Q4 2014.
- Funds reported $184M of La Jolla Pharmaceutical Company stock for Q1 2015, up 4.6% quarter-over-quarter.
- 10 funds opened new La Jolla Pharmaceutical Company positions in Q1 2015 and 5 closed out, a net change of +5 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q1 2015 was Fidelity Investments, an estimated $16.2M added.
- The largest La Jolla Pharmaceutical Company seller in Q1 2015 was Broadfin Capital, an estimated $8.47M sold.
Based on aggregated 13F filings for Q1 2015.